Why Akcea Therapeutics Stock Skyrocketed Today
The biotech is being acquired by its largest shareholder.
Akcea Therapeutics, Inc.(AKCA)
NASDAQ
AKCA
Akcea Therapeutics, Inc.
Interactive Chart
News & Analysis: Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. (AKCA) Q2 2020 Earnings Call Transcript
AKCA earnings call for the period ending June 30, 2020.
Akcea Therapeutics, Inc. (AKCA) Q1 2020 Earnings Call Transcript
AKCA earnings call for the period ending March 31, 2020.
Akcea Therapeutics, Inc. (AKCA) Q4 2019 Earnings Call Transcript
AKCA earnings call for the period ending December 31, 2019.
Akcea and Ionis Confirm Positive Trial Results for Hypertriglyceridemia Treatment
Both primary as well as multiple secondary endpoints were met in the trial.
Akcea and Ionis' Triglyceride-Lowering Drug Works in Mid-Stage Clinical Trial
The drug will advance to studies in familial chylomicronemia syndrome and other diseases that result in high triglyceride levels.
5 Reasons 2020 Will Be a Big Year for Ionis Pharmaceuticals
Investors are overly focused on one issue with this stock while the company is making progress on many fronts.
Akcea Therapeutics, Inc. (AKCA) Q3 2019 Earnings Call Transcript
AKCA earnings call for the period ending September 30, 2019.
What Happened in the Stock Market Today
Aksea Therapeutics is teaming up with Pfizer on a new drug, and HEXO got downgraded after the resignation of its CFO.
Here's Why Akcea Therapeutics Jumped 30% Today
A licensing deal gives investors confidence in a turnaround.
